The International Workshop on Chronic Lymphocytic Leukemia (IWCLL) proposed criteria for assessing a patient's response to therapy for chronic lymphocytic leukemia (CLL).
Findings |
Response |
no evidence of disease (see below) |
complete |
change from Binet Stage C to B, OR change from Binet Stage C to A, OR change from Binet Stage B to A |
partial |
no change in the stage of disease |
stable |
change from Binet stage A to B, OR change from Binet stage A to C, OR change from Binet stage B to C |
progressive |
Clinical and routine laboratory markers of complete response to treatment:
(1) absence of constitutional symptoms (fever, night sweats, weight loss)
(2) resolution of lymphadenopathy
(3) absence of splenomegaly
(4) absence of hepatomegaly
(5) absolute lymphocyte counts < 4,000 per µL
(6) absolute neutrophil counts > 1,500 per µL
(7) platelet counts > 100,000 per µL
(8) hemoglobin > 11 g/dL
(9) normal findings on bone marrow examination, OR the presence of focal or nodular lymphoid infiltrates (absence of diffuse infiltration)
Immunologic and molecular markers of complete response to treatment:
(1) normalization of the T and B cell counts
(2) balanced kappa and lambda light chain ratio
(3) < 25% CD5-positive B cells
(4) normal cytogenetics
(5) normalization of gene rearrangement studies
Specialty: Hematology Oncology